David Miklos, MD, associate professor of medicine, Blood and Marrow Transplantation, and clinical director of Cancer Cell Therapy at Stanford University Medical Center, discusses the safety profile of KTE-X19 in mantle cell lymphoma (MCL).
Website: onclive.com
Twitter: twitter.com/OncLive
Facebook: facebook.com/OncLive/
LinkedIn: linkedin.com/company/onclive
- Dr. Miklos on the Safety Profile of KTE-X19 in MCL ( Download)
- Dr. Wang on the Safety Profile of KTE-X19 in MCL ( Download)
- Dr. Miklos on Anticipated Sequencing Challenges With KTE-X19 in MCL ( Download)
- Dr. Miklos on the Results of the ZUMA-2 Trial in MCL ( Download)
- Managing Known CAR T-Cell Toxicities With KTE-X19 ( Download)
- Dr. Smith on Safety Profiles of BTK Inhibitors in MCL ( Download)
- Dr. Wang on Unique Properties of KTE-X19 in Relapsed/Refractory MCL ( Download)
- Dr. Wang on the Impact of KTE-X19 on Outcomes in Higher- Versus Lower-Risk MCL ( Download)
- Dr. Wang on the Efficacy of KTE-X19 in Low- and High-Risk R/R MCL ( Download)
- ZUMA-2 Trial Demonstrates Efficacy in Mantle Cell Lymphoma ( Download)
- Dr. Goy on the Progression of MCL Treatment ( Download)
- Dr. Smith on Frontline Treatment Options in MCL ( Download)
- Dr. Goy on the Evolution of Treatment Selection in MCL ( Download)
- Dr. Gerson on Clinical Trial Accrual in MCL ( Download)
- Dr. David Miklos_Car-T ( Download)
